FDA Clearance Achieved By This Health Company For New Cancer Drug
FDA Clears Carisma Therapeutics' Novel HER2-Targeting CAR-Monocyte, CT-0525: What it Means for You.
In a major advancement for the field of cancer therapy, Carisma Therapeutics has recently announced the FDA clearance of its Investigational New Drug (IND) application for CT-0525. This novel approach to cancer treatment leverages HER2-targeting CAR-monocytes and could potentially revolutionize the way we combat solid tumors.
…